The PE Ratio as of November 2024 (TTM) for Harmony Biosciences Holdings, Inc. (HRMY) is 16.15

According to Harmony Biosciences Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 16.15. This represents a change of -18.77% compared to the average of 19.88 of the last 4 quarters.

Harmony Biosciences Holdings, Inc. (HRMY) Historical PE Ratio (quarterly & annually)

How has HRMY PE Ratio performed in the past?

The mean historical PE Ratio of Harmony Biosciences Holdings, Inc. over the last ten years is 0.59. The current 16.15 PE Ratio has changed 274.04% with respect to the historical average. Over the past ten years (40 quarters), HRMY's PE Ratio was at its highest in in the September 2020 quarter at 130.14. The PE Ratio was at its lowest in in the June 2020 quarter at -21582.50.

Harmony Biosciences Holdings, Inc. (HRMY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Harmony Biosciences Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Harmony Biosciences Holdings, Inc. (HRMY) Average PE Ratio

How has HRMY PE Ratio performed in the past?

The current PE Ratio of Harmony Biosciences Holdings, Inc. (HRMY) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Harmony Biosciences Holdings, Inc. (HRMY) PE Ratio vs. Peers

How is HRMY’s PE Ratio compared to its peers?

Harmony Biosciences Holdings, Inc.’s PE Ratio is greater than Keros Therapeutics, Inc. (-11.12), greater than Janux Therapeutics, Inc. (-45.40), greater than Fennec Pharmaceuticals Inc. (-120.74), greater than Edgewise Therapeutics, Inc. (-24.30), greater than Pliant Therapeutics, Inc. (-3.91), greater than Syndax Pharmaceuticals, Inc. (-4.63), greater than Revolution Medicines, Inc. (-16.70), greater than Viridian Therapeutics, Inc. (-5.22), greater than Inozyme Pharma, Inc. (-1.84), greater than Ventyx Biosciences, Inc. (-0.86), greater than Nuvalent, Inc. (-27.80), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than Travere Therapeutics, Inc. (-4.04), greater than Structure Therapeutics Inc. (-14.91), greater than Replimune Group, Inc. (-5.51), greater than Nuvectis Pharma, Inc. (-4.54), greater than Lyra Therapeutics, Inc. (-0.13), greater than Kronos Bio, Inc. (-0.64), greater than Gossamer Bio, Inc. (-2.20), greater than IDEAYA Biosciences, Inc. (-12.96), less than Protagonist Therapeutics, Inc. (16.80), greater than Verona Pharma plc (-20.55),

Build a custom stock screener for Harmony Biosciences Holdings, Inc. (HRMY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Harmony Biosciences Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Harmony Biosciences Holdings, Inc. (HRMY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Harmony Biosciences Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.